Skip to main content

Advertisement

Table 1 Screening means and baseline means (post flare) for pain, swollen and tender joint counts and HAQ scores by treatment groups and by concomitant therapy subgroups

From: Do COX-2 inhibitors provide additional pain relief and anti-inflammatory effects in patients with rheumatoid arthritis who are on biological disease-modifying anti-rheumatic drugs and/or corticosteroids? Post-hoc analyses from a randomized clinical trial with etoricoxib

  Placebo Etoricoxib 10/30/60 mg Etoricoxib 90 mg
Screening/Baseline Screening/Baseline Screening/Baseline
Pain VAS    
Neither 42.8/73.4 39.8/69.0* 37.22/70.6
bDMARD 40.2/71.2 39.7/69.4 36.17/67.8
CS 38.9/73.1 42.2/74.9 38.23/72.6
Both 40.1/69.9 42.7/71.5 48.50 / 73.8
66-SJC    
Neither 8.1/16.2 7.3/16.6 7.41/15.8
bDMARD 9.8/16.9 10.1/15.3 10.17/19.1
CS 7.9/15.5 8.9/19.8 7.19 / 14.5
Both 10.2/16.6 11.9/17.2 9.63/18.9
68-TJC    
Neither 13.7/26.5 13.0/26.4 13.86/25.8
bDMARD 12.1/29.6 16.8/31.9 15.86/28.9
CS 12.5/26.2 12.8/26.8 14.25/25.4
Both 13.8/29.1 14.2/29.6 12.81/28.8
HAQ-score    
Neither 0.99/1.32 0.89/1.18 0.89/1.14
bDMARD 0.86/1.32 1.12/1.45 1.01/1.35
CS 1.00/1.28 1.02/1.42 0.97/1.26
Both 1.57/1.67 1.10/1.43** 1.45/1.64
  1. bDMARDs = Biological disease-modifying antirheumatic drugs;CS = Corticosteroids;VAS = Visual analogue scale.
  2. 66-SJC = Swollen joint count of 66 joints; 68-TJC = Tender joint count of 68 joints; HAQ = Health assessment questionnaire.
  3. *p = 0.050 for difference between baseline values for placebo and etoricoxib 10/30/60; **p = 0.036 for difference between screening values for placebo and etoricoxib (Other than these two instances out of the 96 treatment comparisons that were conducted, there were no consistently observed statistical differences in screening/baseline values).